Señales en vivo de ORTX | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (23 ene 2024 @ 16:00):

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States...

Stats
Volumen de hoy	372 349
Volumen promedio	105 224
Capitalización de mercado	380.11M
EPS	$0 ( 2024-03-04 )
Próxima fecha de ganancias	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.07
ATR14	$0.0590 (0.35%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-24	Secor Alicia	Sell	46 000	Stock Option (Right to Buy)
2024-01-24	Secor Alicia	Sell	105 000	Stock Option (Right to Buy)
2024-01-24	Geraghty James A	Sell	44 391	Ordinary Shares
2024-01-24	Geraghty James A	Sell	46 000	Stock Option (Right to Buy)
2024-01-24	Geraghty James A	Sell	105 000	Stock Option (Right to Buy)

INSIDER POWER
-32.53
Last 99 transactions
Buy: 13 341 271 \| Sell: 6 351 136

Volumen Correlación

Largo: 0.03 (neutral)

Corto: 0.00 (neutral)

Signal:(85.364) Neutral

Orchard Therapeutics PLC Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Orchard Therapeutics PLC Correlación - Moneda/Commodity

0.88
( strong )

0.69
( moderate )

-0.31
( neutral )

0.75
( moderate )

0.09
( neutral )

-0.25
( neutral )

Orchard Therapeutics PLC Finanzas

Annual	2022
Ingresos:	$6.99M
Beneficio Bruto:	$4.55M (65.17 %)
EPS:	$-0.610

FY	2022
Ingresos:	$6.99M
Beneficio Bruto:	$4.55M (65.17 %)
EPS:	$-0.610

FY	2021
Ingresos:	$1.68M
Beneficio Bruto:	$1.45M (86.51 %)
EPS:	$-1.170

FY	2020
Ingresos:	$2.60M
Beneficio Bruto:	$1.74M (66.97 %)
EPS:	$-1.530

Financial Reports:

No articles found.

Orchard Therapeutics PLC

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. It has a strategic collaboration agreement with Pharming Group N.V. for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.